• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.

作者信息

Rini Brian I, Garcia Jorge A, Cooney Matthew M, Elson Paul, Tyler Allison, Beatty Kristi, Bokar Joseph, Ivy Percy, Chen Helen X, Dowlati Afshin, Dreicer Robert

出版信息

J Clin Oncol. 2010 Jun 10;28(17):e284-5; author reply e286-7. doi: 10.1200/JCO.2009.27.1759. Epub 2010 May 3.

DOI:10.1200/JCO.2009.27.1759
PMID:20439632
Abstract
摘要

相似文献

1
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.舒尼替尼联合贝伐单抗治疗肾细胞癌的毒性反应
J Clin Oncol. 2010 Jun 10;28(17):e284-5; author reply e286-7. doi: 10.1200/JCO.2009.27.1759. Epub 2010 May 3.
2
From theoretical synergy to clinical supra-additive toxicity.从理论协同作用到临床超相加毒性。
J Clin Oncol. 2009 Mar 20;27(9):1359-61. doi: 10.1200/JCO.2008.20.8595. Epub 2009 Feb 17.
3
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.贝伐单抗联合递增剂量舒尼替尼治疗转移性肾细胞癌的I期试验。
J Clin Oncol. 2009 Mar 20;27(9):1432-9. doi: 10.1200/JCO.2008.19.0108. Epub 2009 Feb 17.
4
Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.贝伐珠单抗-舒尼替尼联合治疗索拉非尼治疗失败的转移性肾细胞癌的挽救治疗：病例系列。
Eur Urol. 2009 Jul;56(1):207-11; quiz 211. doi: 10.1016/j.eururo.2009.01.001. Epub 2009 Jan 13.
5
Tolerability of first-line therapy for metastatic renal cell carcinoma.转移性肾细胞癌一线治疗的耐受性
Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26.
6
Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.对“一线转移性肾细胞癌治疗中不良事件管理的成本：贝伐单抗联合干扰素-α2a与舒尼替尼的比较”的评论
Br J Cancer. 2010 Oct 12;103(8):1307-8; author reply 1309-10. doi: 10.1038/sj.bjc.6605886. Epub 2010 Sep 14.
7
Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.关于：“一线转移性肾细胞癌治疗中不良事件管理的成本：贝伐单抗联合α-干扰素2a与舒尼替尼的比较”
Br J Cancer. 2010 Mar 30;102(7):1196-7. doi: 10.1038/sj.bjc.6605585. Epub 2010 Feb 23.
8
[First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO].
Urologe A. 2016 Sep;55(9):1242-3. doi: 10.1007/s00120-016-0188-0.
9
Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.用于肾细胞癌的新型药物需要新型选择模式来优化一线治疗。
Cancer Treat Rev. 2009 May;35(3):289-96. doi: 10.1016/j.ctrv.2009.01.004. Epub 2009 Feb 15.
10
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.转移性肾细胞癌的靶向治疗：毒性及给药策略概述
Oncologist. 2008 Oct;13(10):1084-96. doi: 10.1634/theoncologist.2008-0120. Epub 2008 Oct 6.

引用本文的文献

1
A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma.贝伐单抗与血管内皮生长因子受体靶向疫苗联合应用于恶性胶质瘤患者引起不良事件的初步研究。
Vaccines (Basel). 2020 Sep 2;8(3):498. doi: 10.3390/vaccines8030498.
2
Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance.在抗血管生成治疗耐药的转移模型中增强西他拉尼的疗效。
PLoS One. 2019 Aug 1;14(8):e0220101. doi: 10.1371/journal.pone.0220101. eCollection 2019.
3
Sunitinib in the treatment of metastatic renal cell carcinoma.
舒尼替尼治疗转移性肾细胞癌。
Ther Adv Urol. 2016 Dec;8(6):348-371. doi: 10.1177/1756287216663979. Epub 2016 Aug 23.
4
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).BEST：血管内皮生长因子、RAF激酶和雷帕霉素哺乳动物靶点联合靶向治疗（贝伐单抗、索拉非尼和替西罗莫司）用于晚期肾细胞癌的随机II期研究——东部肿瘤协作组-美国放射肿瘤学会癌症研究组（E2804）试验
J Clin Oncol. 2015 Jul 20;33(21):2384-91. doi: 10.1200/JCO.2015.60.9727. Epub 2015 Jun 15.
5
Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA.肾切除术后转移性肾细胞癌与抗血管内皮生长因子诱导的肾血栓性微血管病的罕见关联。
NDT Plus. 2011 Feb;4(1):78-9. doi: 10.1093/ndtplus/sfq178. Epub 2010 Oct 7.
6
Sequencing systemic therapies for metastatic kidney cancer.序贯全身治疗转移性肾细胞癌。
Curr Treat Options Oncol. 2015 Jan;16(1):316. doi: 10.1007/s11864-014-0316-2.
7
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.晚期实体恶性肿瘤中的双重VEGF/VEGFR抑制：临床效果和药效学生物标志物
Cancer Biol Ther. 2014 Aug;15(8):975-81. doi: 10.4161/cbt.29187. Epub 2014 May 19.
8
Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.舒尼替尼的肾脏不良反应及其临床意义：韩国单中心经验
Korean J Intern Med. 2014 Jan;29(1):40-8. doi: 10.3904/kjim.2014.29.1.40. Epub 2014 Jan 2.
9
A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies.舒尼替尼序贯贝伐珠单抗治疗肾细胞癌和其他晚期实体瘤的 I 期药效学试验。
Cancer Chemother Pharmacol. 2014 Mar;73(3):485-93. doi: 10.1007/s00280-013-2373-9. Epub 2014 Jan 12.
10
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).贝伐珠单抗（BVZ）联合伊立替康（CPT-11）治疗复发性中枢神经系统肿瘤患儿的相关毒性：儿科脑瘤协作组研究（PBTC-022）。
Cancer. 2013 Dec 1;119(23):4180-7. doi: 10.1002/cncr.28343. Epub 2013 Sep 19.